These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 31787752)

  • 1. Pharmacogenomic biomarker information differences between drug labels in the United States and Hungary: implementation from medical practitioner view.
    Varnai R; Szabo I; Tarlos G; Szentpeteri LJ; Sik A; Balogh S; Sipeky C
    Pharmacogenomics J; 2020 Jun; 20(3):380-387. PubMed ID: 31787752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guidance for pharmacogenomic biomarker testing in labels of FDA-approved drugs.
    Vivot A; Boutron I; Ravaud P; Porcher R
    Genet Med; 2015 Sep; 17(9):733-8. PubMed ID: 25521333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenomic Biomarkers: an FDA Perspective on Utilization in Biological Product Labeling.
    Schuck RN; Grillo JA
    AAPS J; 2016 May; 18(3):573-7. PubMed ID: 26912182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing cytochrome P450 pharmacogenetic information available on United States drug labels and European Union Summaries of Product Characteristics.
    Reis-Pardal J; Rodrigues A; Rodrigues E; Fernandez-Llimos F
    Pharmacogenomics J; 2017 Dec; 17(6):488-493. PubMed ID: 27241061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use.
    Frueh FW; Amur S; Mummaneni P; Epstein RS; Aubert RE; DeLuca TM; Verbrugge RR; Burckart GJ; Lesko LJ
    Pharmacotherapy; 2008 Aug; 28(8):992-8. PubMed ID: 18657016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenomic biomarker information in FDA-approved paediatric drug labels.
    Kim T; Han N; Sohn M; Oh JM; Lee EK; Ji E; Kim IW
    Basic Clin Pharmacol Toxicol; 2015 May; 116(5):438-44. PubMed ID: 25348905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenomic information in the Warning section of drug labels: A comparison between labels in the United States and those in five other countries/regions.
    Imatoh T; Sai K; Saito Y
    J Clin Pharm Ther; 2018 Aug; 43(4):493-499. PubMed ID: 29682780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in pharmacogenomic biomarker information in package inserts from the United States, the United Kingdom and Japan.
    Shimazawa R; Ikeda M
    J Clin Pharm Ther; 2013 Dec; 38(6):468-75. PubMed ID: 23895776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical evidence supporting pharmacogenomic biomarker testing provided in US Food and Drug Administration drug labels.
    Wang B; Canestaro WJ; Choudhry NK
    JAMA Intern Med; 2014 Dec; 174(12):1938-44. PubMed ID: 25317785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study of pharmacogenomic information in FDA-approved drug labeling to facilitate application of precision medicine.
    Mehta D; Uber R; Ingle T; Li C; Liu Z; Thakkar S; Ning B; Wu L; Yang J; Harris S; Zhou G; Xu J; Tong W; Lesko L; Fang H
    Drug Discov Today; 2020 May; 25(5):813-820. PubMed ID: 32032705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Current Regulation and Guidelines of Pharmacogenomic Drug Labels: Opportunities for Improvements.
    Shekhani R; Steinacher L; Swen JJ; Ingelman-Sundberg M
    Clin Pharmacol Ther; 2020 May; 107(5):1240-1255. PubMed ID: 31715018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenomic biomarkers in drug labels: what do they tell us?
    Tutton R
    Pharmacogenomics; 2014 Feb; 15(3):297-304. PubMed ID: 24533709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenomic information from CPIC and DPWG guidelines and its application on drug labels.
    Yoon DY; Lee S; Ban MS; Jang IJ; Lee S
    Transl Clin Pharmacol; 2020 Dec; 28(4):189-198. PubMed ID: 33425802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenomic biomarkers: Interpretation of information included in United States and Japanese drug labels.
    Shimazawa R; Ikeda M
    J Clin Pharm Ther; 2018 Aug; 43(4):500-506. PubMed ID: 29722046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Similarities and differences between US and Japan as to pharmacogenomic biomarker information in drug labels.
    Otsubo Y; Asahina Y; Noguchi A; Sato Y; Ando Y; Uyama Y
    Drug Metab Pharmacokinet; 2012; 27(1):142-9. PubMed ID: 22201121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenomic information in FDA-approved drug labels: Application to pediatric patients.
    Green DJ; Mummaneni P; Kim IW; Oh JM; Pacanowski M; Burckart GJ
    Clin Pharmacol Ther; 2016 Jun; 99(6):622-32. PubMed ID: 26693845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective analysis of actionable pharmacogenetic/genomic biomarker language in FDA labels.
    Yamazaki S
    Clin Transl Sci; 2021 Jul; 14(4):1412-1422. PubMed ID: 33742770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Learning from product labels and label changes: how to build pharmacogenomics into drug-development programs.
    Surh LC; Pacanowski MA; Haga SB; Hobbs S; Lesko LJ; Gottlieb S; Papaluca-Amati M; Patterson SD; Hughes AR; Kim MJ; Close SL; Mosteller M; Zineh I; Dechairo B; Cohen NA
    Pharmacogenomics; 2010 Dec; 11(12):1637-47. PubMed ID: 21142906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Trial Designs to Support Clinical Utility of Pharmacogenomic Testing.
    Drozda K; Pacanowski MA
    Pharmacotherapy; 2017 Sep; 37(9):1000-1004. PubMed ID: 28605049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterizing Pharmacogenomic-Guided Medication Use With a Clinical Data Repository.
    Mathias PC; Hendrix N; Wang WJ; Keyloun K; Khelifi M; Tarczy-Hornoch P; Devine B
    Clin Pharmacol Ther; 2017 Aug; 102(2):340-348. PubMed ID: 28073152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.